Opicinumab

Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis[1][2].

Product Specifications

CAS Number

[1422268-07-2]

Product Name Alternative

BIIB033

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/opicinumab.html

Purity

99.5

Solubility

10 mM in DMSO

Smiles

[Opicinumab]

Molecular Weight

(145.2 kDa)

References & Citations

[1]Cadavid D, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW) : a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar;16 (3) :189-199.|[2]Cadavid D, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY) : a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 Sep;18 (9) :845-856.